

# Arnold G Vulto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6433844/publications.pdf>

Version: 2024-02-01

54  
papers

1,591  
citations

361413

20  
h-index

330143

37  
g-index

54  
all docs

54  
docs citations

54  
times ranked

1773  
citing authors

#	ARTICLE	IF	CITATIONS
1	Policies for biosimilar uptake in Europe: An overview. PLoS ONE, 2017, 12, e0190147.	2.5	153
2	The process defines the product: what really matters in biosimilar design and production?. Rheumatology, 2017, 56, iv14-iv29.	1.9	110
3	The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. Clinical Pharmacology and Therapeutics, 2020, 108, 734-755.	4.7	86
4	Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. BioDrugs, 2018, 32, 397-404.	4.6	82
5	The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape. Frontiers in Pharmacology, 2017, 8, 314.	3.5	80
6	Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!. BioDrugs, 2020, 34, 159-170.	4.6	75
7	Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human. Clinical Cancer Research, 2018, 24, 766-776.	7.0	68
8	Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies. Frontiers in Pharmacology, 2016, 7, 193.	3.5	65
9	Barriers to the Uptake of Biosimilars and Possible Solutions: A Belgian Case Study. Pharmacoeconomics, 2014, 32, 681-691.	3.3	64
10	e-Monitoring of Asthma Therapy to Improve Compliance in children (e-MATIC): a randomised controlled trial. European Respiratory Journal, 2016, 48, 758-767.	6.7	54
11	The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. British Journal of Cancer, 2019, 121, 199-210.	6.4	48
12	The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. Frontiers in Pharmacology, 2020, 11, 591134.	3.5	44
13	European Stakeholder Learnings Regarding Biosimilars: Part I – Improving Biosimilar Understanding and Adoption. BioDrugs, 2020, 34, 783-796.	4.6	39
14	Use of Biosimilars in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2019, 68, 144-153.	1.8	38
15	Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies. Clinical Cancer Research, 2022, 28, 1572-1585.	7.0	36
16	European Stakeholder Learnings Regarding Biosimilars: Part II – Improving Biosimilar Use in Clinical Practice. BioDrugs, 2020, 34, 797-808.	4.6	33
17	An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?. MAbs, 2020, 12, 1743517.	5.2	31
18	Physicians' acceptance of pharmacists' interventions in daily hospital practice. International Journal of Clinical Pharmacy, 2020, 42, 141-149.	2.1	30

#	ARTICLE	IF	CITATIONS
19	Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. <i>Pharmaceuticals</i> , 2021, 14, 117.	3.8	30
20	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1â€”Biosimilar and Originator Infliximab in the Hospital Setting. <i>BioDrugs</i> , 2019, 33, 285-297.	4.6	23
21	A health economic guide to market access of biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 9-17.	3.1	23
22	Ketanserin versus dihydralazine for the treatment of severe hypertension in early-onset preeclampsia: a double blind randomized controlled trial. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 189, 106-111.	1.1	22
23	Manipulation of oral medication for children by parents and nurses occurs frequently and is often not supported by instructions. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2019, 108, 1475-1481.	1.5	22
24	Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel. <i>Frontiers in Pharmacology</i> , 2017, 8, 322.	3.5	21
25	Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. <i>Pharmaceuticals</i> , 2020, 13, 324.	3.8	20
26	Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure. <i>BioDrugs</i> , 2020, 34, 255-263.	4.6	19
27	Off-Patent Biologicals and Biosimilars Tendering in Europeâ€”A Proposal towards More Sustainable Practices. <i>Pharmaceuticals</i> , 2021, 14, 499.	3.8	18
28	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2â€”Biosimilar and Originator Etanercept in the Outpatient Setting. <i>BioDrugs</i> , 2019, 33, 299-306.	4.6	16
29	Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging. <i>Frontiers in Medicine</i> , 2022, 9, 820755.	2.6	16
30	Risk management of biosimilars in oncology: each medicine is a work in progress. <i>Targeted Oncology</i> , 2012, 7, 43-49.	3.6	15
31	Non-adherence to inhaled corticosteroids and the risk of asthma exacerbations in children. <i>Patient Preference and Adherence</i> , 2016, 10, 531.	1.8	15
32	Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe. <i>BioDrugs</i> , 2022, 36, 217-229.	4.6	15
33	Overcoming challenges in market access of generic medicines in the European Union. <i>Journal of Generic Medicines</i> , 2012, 9, 21-28.	0.2	14
34	Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1728-1739.	2.4	14
35	Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 644187.	3.5	14
36	How to select a biosimilar. <i>European Journal of Hospital Pharmacy</i> , 2013, 20, 275-286.	1.1	13

#	ARTICLE	IF	CITATIONS
37	Biosimilars in Belgium: a proposal for a more competitive market. <i>Acta Clinica Belgica</i> , 2021, 76, 441-452.	1.2	13
38	Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 154, 105501.	4.0	11
39	A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study. <i>BioDrugs</i> , 2021, 35, 75-87.	4.6	11
40	Interchangeability of Biosimilars: Overcoming the Final Hurdles. <i>Drugs</i> , 2021, 81, 1897-1903.	10.9	11
41	Where a cheap medicine is not the same as a generic medicine: the Belgian case. <i>Journal of Pharmaceutical Health Services Research</i> , 2011, 2, 185-189.	0.6	9
42	Delivering on the Promise of Biosimilars. <i>BioDrugs</i> , 2019, 33, 599-602.	4.6	8
43	Biologicals and Biosimilars in Hematology: The Case of Rituximab. <i>HemaSphere</i> , 2019, 3, e322.	2.7	8
44	Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review. <i>Pharmaceuticals</i> , 2020, 13, 400.	3.8	8
45	Economic evaluation of biosimilars for reimbursement purposes – what, when, how?. <i>Journal of Market Access &amp; Health Policy</i> , 2020, 8, 1739509.	1.5	8
46	Antithrombotic stewardship: a multidisciplinary team approach towards improving antithrombotic therapy outcomes during and after hospitalisation: a study protocol. <i>BMJ Open</i> , 2016, 6, e011537.	1.9	7
47	Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 53.	2.4	7
48	Availability of age-appropriate paediatric formulations in the Netherlands: the need in daily clinical practice remains. <i>European Journal of Hospital Pharmacy</i> , 2021, 28, 306-312.	1.1	6
49	Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care. <i>Frontiers in Pharmacology</i> , 2021, 12, 789640.	3.5	6
50	Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study. <i>Pharmaceuticals</i> , 2021, 14, 450.	3.8	4
51	Lentiviral Stem Cell Gene Therapy for Pompe Disease. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, S64-S64.	2.6	3
52	Lentiviral Stem Cell Gene Therapy for Pompe Disease. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, S64.	2.6	2
53	Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	2
54	When Will American Patients Start Benefitting From Biosimilars?. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1044-1047.	3.0	1